APRAMEYA vs CORONA: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. APRAMEYA shows a lower P/E and lower leverage, while CORONA REMEDIES shows a higher ROE, a higher dividend yield and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APRAMEYA leads 6; CORONA leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | APRAMEYA | CORONA |
|---|---|---|
| Live Price | — | ₹2,201.8 |
| Day Change | — | 1.48% |
| Volume | — | 12,123 |
| 52-Week High | — | ₹2,292.4 |
| 52-Week Low | — | ₹1,336.6 |
| Distance from 52W High | — | -3.95% |
Valuation
| Metric | APRAMEYA | CORONA |
|---|---|---|
| Market Cap | ₹217 Cr | ₹13,492 Cr |
| P/E Ratio | 60.82x | 67.79x |
| P/B Ratio | 0x | 18.06x |
| EPS | ₹2.68 | ₹9.83 |
| Book Value | ₹36.54 | ₹122.12 |
| Dividend Yield | 0% | 0.45% |
Growth
| Metric | APRAMEYA | CORONA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0.7% | 0% |
| Qtr Profit Growth | 1.73% | 0.02% |
Profitability & Leverage
| Metric | APRAMEYA | CORONA |
|---|---|---|
| ROE | 7.37% | 24.78% |
| ROCE | 10.07% | 21.44% |
| Net Margin | 0% | 13.19% |
| Operating Margin | 19.83% | 17.61% |
| Debt to Equity | 0.1x | 0.19x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | APRAMEYA | CORONA |
|---|---|---|
| Promoter Holding | 74.05%▲ 0.52 pp | 69% |
| FII Holding | 0% | 3.63%▲ 1.38 pp |
| DII Holding | 0.7%▼ 0.07 pp | 12.9%▲ 5.88 pp |
| Public Holding | 25.24%▼ 0.46 pp | 14.48%▼ 7.26 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and CORONA REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.